Results 21 to 30 of about 18,748 (206)

Anti-Androgen Receptor Therapies in Prostate Cancer: A Brief Update and Perspective

Frontiers in Oncology, 2022
Prostate cancer is a major health issue in western countries and is the second leading cause of cancer death in American men. Prostate cancer depends on the androgen receptor (AR), a transcriptional factor critical for prostate cancer growth and ...
Jian Huang, Biyun Lin, Benyi Li
doaj   +1 more source

Extract and the Main Component, Cordycepin, Modulate the Functions of Prostate Cancer Cells Partially Through the Adenosine A1 Receptor

Natural Product Communications, 2022
Our previous study demonstrated that an extract of Cordyceps militaris (CM) derived from Samia Cynthia ricini inhibits testosterone-induced prostate hypertrophy in an animal model.
Kazuya Kusama, Takumi Suzuki, Ryosuke Motohashi, Takumi Nobusawa, Koichiro Ota, Mana Azumi, Mikihiro Yoshie, Hiroaki Miyaoka, Kazuhiro Tamura   +8 more
doaj   +1 more source

Endocrine disrupting potential of selected azole and organophosphorus pesticide products through suppressing the dimerization of human androgen receptor in genomic pathway

Ecotoxicology and Environmental Safety, 2022
Several pesticides widely used in agriculture have been considered to be endocrine disrupting chemicals through their binding affinities to estrogen or androgen receptors.
Da-Woon Jung, Da-Hyun Jeong, Hee-Seok Lee   +2 more
doaj   +1 more source

Effect of small molecules modulating androgen receptor (SARMs) in human prostate cancer models.

PLoS ONE, 2013
The management of hormone-refractory prostate cancer represents a major challenge in the therapy of this tumor, and identification of novel androgen receptor antagonists is needed to render treatment more effective.
Anna Tesei, Carlo Leonetti, Marzia Di Donato, Elisa Gabucci, Manuela Porru, Greta Varchi, Andrea Guerrini, Dino Amadori, Chiara Arienti, Sara Pignatta, Giulia Paganelli, Michele Caraglia, Gabriella Castoria, Wainer Zoli   +13 more
doaj   +1 more source

Interleukin-10 Induces Expression of Neuroendocrine Markers and PDL1 in Prostate Cancer Cells

Prostate Cancer, 2020
Interleukin-10 (IL10) is best studied for its inhibitory action on immune cells and ability to suppress an antitumour immune response. But IL10 also exerts direct effects on nonimmune cells such as prostate cancer epithelial cells.
Abrar Samiea, Jeff S. J. Yoon, Christopher J. Ong, Amina Zoubeidi, Thomas C. Chamberlain, Alice L.-F. Mui   +5 more
doaj   +1 more source

Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer

Cell Death and Disease, 2022
Androgen receptor (AR) plays an important role in the progression of prostate cancer and has been targeted by castration or AR-antagonists. The emergence of castration-resistant prostate cancer (CRPC) after androgen deprivation therapy (ADT) is ...
Xuanrong Chen, Yi Shao, Wanqing Wei, Shimiao Zhu, Yang Li, Yutong Chen, Hanling Li, Hao Tian, Guijiang Sun, Yuanjie Niu, Zhiqun Shang   +10 more
doaj   +1 more source

In silico comparison between the mutated and wild-type androgen receptors and their influence on the selection of optimum androgenic receptor blockers for the treatment of prostate cancer [version 4; peer review: 2 approved]

F1000Research
Background: Prostate cancer is a disease that occurs in men aged more than 50 years. In Iraq, 8.89 men per 100,000 population suffer from prostate cancer, with the incidence being 14,016 cases and mortality being 6,367 cases.
Hany Akeel Al-Hussaniy, Mohammed J. AL-Zobaidy, Zahraa S. Al-tameemi   +2 more
doaj   +1 more source

SIRNA-directed in vivo silencing of androgen receptor inhibits the growth of castration-resistant prostate carcinomas. [PDF]

PLoS ONE, 2007
BACKGROUND: Prostate carcinomas are initially dependent on androgens, and castration or androgen antagonists inhibit their growth. After some time though, tumors become resistant and recur with a poor prognosis.
Daniel Compagno, Carole Merle, Aurélie Morin, Cristèle Gilbert, Jacques R R Mathieu, Aline Bozec, Claire Mauduit, Mohammed Benahmed, Florence Cabon   +8 more
doaj   +1 more source

MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer

Molecular Cancer, 2011
Background Hormone therapy is the standard of care for newly diagnosed or recurrent prostate cancers. It uses anti-androgen agents, castration, or both to eliminate cancer promoting effect of testicular androgen. The p53 tumor suppressor controls a major
Packman Kathryn, Xia Mingxuan, Kolinsky Kenneth, Higgins Brian, Tovar Christian, Heimbrook David C, Vassilev Lyubomir T   +6 more
doaj   +1 more source

Epigenetic reprogramming of lineage switching in cancer

FEBS Letters, EarlyView.
Cancer cells rarely commit to a single identity. Epigenetic mechanisms and tumor microenvironment cues push epithelial cells toward flexible, hybrid states that can shift into mesenchymal, neuroendocrine, or stem‐like fates, driving metastasis, drug resistance, and tumor heterogeneity. Targeting the epigenetic regulators behind these transitions, using
Ezgi Boyvatlı, Burcu Akman, Ezgi Bağırsakçı, Nese Atabey, Serap Erkek‐Ozhan   +4 more
wiley   +1 more source